Skip to main content
Only direct cytotoxic targets are shown
Gene
Drug Category
Drug Class
Download CSV
Gene NCT ID Antigen/Ligand Binding Type Drug Name Drug NCI Concept Drug Category Drug Class Drug Description Drug Mechanism of Action Target Cytotoxicity Mechanism Disease Disease Type Tissue OncoTree Main Type OncoTree Name Annotation Status
ULBP2 NCT06478459 ULBP2 receptor ligand recognition NKG2D CAR-NK cells CAR NK Cellular Therapy Engineered natural killer cells expressing an NKG2D-based chimeric antigen receptor; administered via endoscopic ultrasound–guided intratumoral injection plus two intravenous infusions to recognize NKG2D ligands (e.g., MICA, MICB, ULBP family) and induce NK-mediated cytotoxicity. Engineered NK cells expressing an NKG2D-based chimeric antigen receptor bind NKG2D ligands (e.g., MICA, MICB, ULBP family) on tumor cells, triggering NK activation and cytotoxicity (perforin/granzyme release, cytokine production) to kill cancer cells. NKG2D CAR-NK cells bind ULBP2 on target cells, triggering NK activation and degranulation (perforin/granzyme–mediated apoptosis), with possible contribution from death receptor pathways (FasL/TRAIL). Pancreatic Cancer, Non-resectable CANCER Pancreas Pancreatic Cancer Pancreatic Cancer ai
ULBP3 NCT06478459 ULBP3 receptor ligand recognition NKG2D CAR-NK cells CAR NK Cellular Therapy Engineered natural killer cells expressing an NKG2D-based chimeric antigen receptor; administered via endoscopic ultrasound–guided intratumoral injection plus two intravenous infusions to recognize NKG2D ligands (e.g., MICA, MICB, ULBP family) and induce NK-mediated cytotoxicity. Engineered NK cells expressing an NKG2D-based chimeric antigen receptor bind NKG2D ligands (e.g., MICA, MICB, ULBP family) on tumor cells, triggering NK activation and cytotoxicity (perforin/granzyme release, cytokine production) to kill cancer cells. NKG2D CAR-NK cells bind ULBP3 on target cells, triggering NK activation and degranulation to kill the targets via perforin/granzyme–mediated apoptosis. Pancreatic Cancer, Non-resectable CANCER Pancreas Pancreatic Cancer Pancreatic Cancer ai
RAET1E NCT06478459 ULBP4 receptor ligand recognition NKG2D CAR-NK cells CAR NK Cellular Therapy Engineered natural killer cells expressing an NKG2D-based chimeric antigen receptor; administered via endoscopic ultrasound–guided intratumoral injection plus two intravenous infusions to recognize NKG2D ligands (e.g., MICA, MICB, ULBP family) and induce NK-mediated cytotoxicity. Engineered NK cells expressing an NKG2D-based chimeric antigen receptor bind NKG2D ligands (e.g., MICA, MICB, ULBP family) on tumor cells, triggering NK activation and cytotoxicity (perforin/granzyme release, cytokine production) to kill cancer cells. NKG2D CAR-NK cells recognize ULBP4 (an NKG2D ligand) on target cells, triggering NK activation and killing via immune synapse–mediated degranulation (perforin/granzyme) and death-receptor pathways. Pancreatic Cancer, Non-resectable CANCER Pancreas Pancreatic Cancer Pancreatic Cancer ai
RAET1G NCT06478459 ULBP5 receptor ligand recognition NKG2D CAR-NK cells CAR NK Cellular Therapy Engineered natural killer cells expressing an NKG2D-based chimeric antigen receptor; administered via endoscopic ultrasound–guided intratumoral injection plus two intravenous infusions to recognize NKG2D ligands (e.g., MICA, MICB, ULBP family) and induce NK-mediated cytotoxicity. Engineered NK cells expressing an NKG2D-based chimeric antigen receptor bind NKG2D ligands (e.g., MICA, MICB, ULBP family) on tumor cells, triggering NK activation and cytotoxicity (perforin/granzyme release, cytokine production) to kill cancer cells. NKG2D CAR–NK cells bind ULBP5 on target cells, triggering NK activation and release of perforin/granzymes at the immune synapse, causing apoptotic/lytic killing. Pancreatic Cancer, Non-resectable CANCER Pancreas Pancreatic Cancer Pancreatic Cancer ai
RAET1L NCT06478459 ULBP6 receptor ligand recognition NKG2D CAR-NK cells CAR NK Cellular Therapy Engineered natural killer cells expressing an NKG2D-based chimeric antigen receptor; administered via endoscopic ultrasound–guided intratumoral injection plus two intravenous infusions to recognize NKG2D ligands (e.g., MICA, MICB, ULBP family) and induce NK-mediated cytotoxicity. Engineered NK cells expressing an NKG2D-based chimeric antigen receptor bind NKG2D ligands (e.g., MICA, MICB, ULBP family) on tumor cells, triggering NK activation and cytotoxicity (perforin/granzyme release, cytokine production) to kill cancer cells. NKG2D CAR on NK cells binds ULBP6 on target cells, triggering NK activation and degranulation to kill via perforin/granzyme-mediated apoptosis (with possible FasL/TRAIL death-receptor signaling). Pancreatic Cancer, Non-resectable CANCER Pancreas Pancreatic Cancer Pancreatic Cancer ai
Displaying 2931 - 2935 of 3741